Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

• Status: Not yet recruiting
• Trial end date: 2025-12-01

Summary

This Phase 2, prospective, interventional, active extension study was designed to evaluate the long-term safety, tolerability, pharmacokinetics, and efficacy of NBI-921352 as adjunctive therapy in adult subjects with focal onset seizures who completed 11 weeks of treatment in randomized, double-blind, placebo-controlled Study NBI-921352-FOS2021. Eligible subjects may enroll directly following the completion of the Week 11 study visit of Study NBI-921352-FOS2021 or after a gap following completion of that study.

• Phase: Phase 2

Details

• Lead Sponsor: Neurocrine Biosciences